Urology
Volume 72, Issue 5 , Pages 966-967 , November 2008

Case for Pharmacotherapy Development for Underactive Bladder

  • Michael B. Chancellor

      Affiliations

    • Neurourology Program, Department of Urology, William Beaumont Hospital, Royal Oak, Michigan
    • Corresponding Author InformationReprint requests: Michael Chancellor, M.D., Neurourology Program, Department of Urology, William Beaumont Hospital, 438 Medical Office Building, 3535 West 13 Mile Road, Royal Oak, MI48073
    • ,
  • Jonathan Kaufman

      Affiliations

    • Frontier Group, Pittsburgh, Pennsylvania

Received 7 March 2008 ,Accepted 24 April 2008.

References 

  1. Ukimura O, Kojima M, Iwata T, et al. Ultrasonic measurement of bladder weight as a novel urodynamic modality. Ad Exper Med Biol. 2003;539:311–315
  2. Khullar V, Salvatore S, Cardozo L, et al. A novel technique for measuring bladder wall thickness in women using transvaginal ultrasound. Ultrasound Obstet Gynecol. 1994;4:220–223
  3. Kim JC, Park EY. Nerve growth factor and prostaglandin E in the urine of female patients with overactive bladder. J Urol. 2006;175:1773–1776
  4. Yoshimura N, Chancellor MB. Differential diagnosis and treatment of impaired bladder emptying. Rev Urol. 2004;6(suppl 1):S24–S31
  5. Kim DK, Yoshimura N, Chancellor MB. A pilot study of AAV1/SERCA2a gene transfer in the rat stress urinary incontinence model. J Urol. 2008;179:534–535
  6. Rigby D. Underactive bladder syndrome. Nurs Stand. 2005;19:57–64

 M. B. Chancellor is a consultant to Allergan, Astellas, Cook, Merck, Pfizer, Proctor and Gambles, and Wyeth; and J. Kaufman is a consultant to the Frontier Group.

PII: S0090-4295(08)00529-3

doi: 10.1016/j.urology.2008.04.041

Urology
Volume 72, Issue 5 , Pages 966-967 , November 2008

Article Tools